Trauma Healing

JP2023550301A5Inactive Publication Date: 2024-11-28GRIFOLS WORLDWIDE OPERATIONS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527438
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-25
Filing Date
2021-11-23
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Chronic wounds and ulcers do not heal properly due to disrupted wound healing processes, leading to significant health issues and high healthcare costs, with limited pharmacological interventions available.

Method used

Administering fibrinogenase systemically to reduce plasma viscosity and fibrinogen levels, improving blood circulation and accelerating wound healing.

Benefits of technology

Reduces plasma and whole blood viscosity, enhancing microcirculation and healing rates of chronic wounds and ulcers, particularly in diabetic and vascular disease patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed herein are methods and compositions for the treatment of wounds and ulcers in patients, particularly those suffering from chronic non-healing wounds and ulcers. Fibrinogenases, such as plasmin, have shown utility in reducing plasma and / or blood viscosity, resulting in improved wound and ulcer healing in patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to methods and compositions for the treatment of wounds and ulcers in patients, particularly patients suffering from chronic non-healing wounds and ulcers. The present invention details the hitherto unreported usefulness of fibrinogenase, for example, plasmin, a serine protease, in the treatment of said wounds and ulcers.

Background Art

[0002] In normal skin, the epidermis and dermis exist in a state of steady equilibrium and form a protective barrier against the external environment. When the protective barrier is breached, the process of wound healing, which involves a complex set of biochemical events occurring in a tightly organized cascade to repair the damage, is immediately initiated. The classical model of wound healing is divided into four consecutive but overlapping stages: (1) hemostasis, (2) inflammation, (3) proliferation, and (4) remodeling.

[0003] In the homeostasis of stage 1, platelets (thrombocytes) are mobilized to the site of injury and form a fibrin thrombus to prevent active bleeding. In the inflammatory stage, bacteria and debris are phagocytosed and removed, and factors that cause the migration and division of cells involved in the proliferation stage are released. The proliferation stage is characterized by angiogenesis, collagen deposition, granulation tissue formation, epithelialization, and wound contraction. In fibroplasia and granulation tissue formation, fibroblasts grow and form a new provisional extracellular matrix (ECM) by providing collagen and fibronectin. At the same time, epithelial cells proliferate and "crawl" over the wound bed, resulting in re-epithelialization of the epidermis that provides coverage of the new tissue. As the healing process continues, the wound decreases in size by the action of myofibroblasts. In the final remodeling stage, type III collagen, which is present in large numbers during proliferation, is replaced by type I collagen. The initially disrupted collagen fibers are repositioned, cross-linked, and aligned along the tension lines.

[0004] The wound healing process is sensitive to interruptions and prone to disruption, leading to the formation of non-healing chronic wounds. In healthy adults, four stages of wound healing progress naturally, and wounds can heal within two to three weeks. In less fortunate individuals, the body's natural healing process can be interrupted or reduced, resulting in much delayed wound healing. These wounds are referred to as chronic wounds (wounds that do not heal for more than four weeks despite normal treatment) and are most common in people with diabetes, hypertension, obesity, and other vascular diseases. If left untreated or uncareful, chronic wounds can lead to pain, infection, disability, and potentially amputation of the affected limb. Non-healing wounds represent a significant burden for both patients and the healthcare system. Nearly 15% of Medicare beneficiaries in the United States suffer from chronic non-healing wounds, and the annual Medicare cost is estimated to be between $28.1 billion and $31.7 billion. See Nussbaun SR et al., "An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds," Value in Health, 2018, Vol. 21, Issue 1, pp. 27-32.

[0005] Strategies used by healthcare professionals to accelerate wound healing include compression techniques, vascular regeneration strategies for treating arterial ulcers, venous surgical interventions for venous ulcers, negative pressure wound therapy, and hyperbaric oxygen therapy. Regarding pharmacological interventions, very few biologically active substances have reached clinical practice, and pharmacological interventions are not widely used for the direct treatment of chronic wounds.

[0006] The plasminogen activator system is a proteolytic system in which plasminogen, a proteolytically inactive enzyme precursor, is converted into plasmin, an active protease, by the action of tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA). The plasminogen activator system plays a role not only in fibrinolysis but also in numerous tissue remodeling processes, including wound healing, by providing space for cell proliferation. See Romer J, Bugge TH, Pyke C et al., Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 1996;2(3):287-292.

[0007] Plasminogen adsorbs to specific sites on fibrin, where it is acted upon by tPA, resulting in the rapid localization and formation of plasmin suitable for cleaving fibrin and other proteins in the extracellular matrix. Plasminogen has also been shown to play a crucial role in activating intracellular signaling events and generating inflammatory responses in the wound healing process; see Ny et al., Blood. 2012;119(24):5879-5887. Ny and colleagues describe plasminogen as an important pro-inflammatory regulator and signaling molecule that accelerates the healing of acute and diabetic wounds. Early in the healing process, circulating plasminogen binds to inflammatory cells and is transported to the wound site, thus locally increasing plasminogen levels, which in turn further leads to cytokine induction, intracellular signaling events, and enhanced early inflammatory responses. Additional plasminogen administration has been reported to accelerate the healing of acute burn wounds in wild-type mice and improve wound healing in diabetic mouse models.

[0008] Based on their plasma stability / half-life and their role in intracellular signaling / inflammation, pharmacological interventions using exogenous plasminogens administered topically near wounds have become a central area of ​​research in the field of wound healing. [Prior art documents] [Patent Documents]

[0009] [Patent Document 1] U.S. Patent No. 4,774,087 [Patent Document 2] U.S. Patent No. 8,420,079 [Non-patent literature]

[0010] [Non-Patent Document 1] Nussbaun SR et al., An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. Value in Health, 2018, V.21, Issue 1, pp. 27-32 [Non-Patent Document 2] Romer J, Bugge TH, Pyke C, et al., Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 1996;2(3):287-292. [Non-Patent Document 3] Ny et al., Blood. 2012;119(24):5879~5887 pp. [Non-Patent Document 4] Palareti G et al., Fibrinogen assays: a collaborative study of six different methods. CISMEL Clin Chem. May 1991; 37(5):714-719. [Non-Patent Document 5] Mackie, Guidelines on fibrinogen assays. British Journal of Haematology, 2003, 121, pages 396~404 [Non-licensed Document 6] Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrunogens. Acta Haematol 1957;17;pages 237~246 [Non-licensed Document 7] Marder VJ. Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin. J Thromb Haemost. 2011;9 Suppl 1:364~373 pages [Non-licensed Document 8] Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. DB Troy, Lippincott Williams & Wilkins, Philadelphia [Non-licensed Document 9] Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New Yor [Non-licensed Document 10] Blomback B., Blomback M. Purification of human and bovine fibrinogen. Arkh. Kem.10, 415, 1956 [Non-licensed Document 11] Novokhatny, V., Acid Stabilised Plasmin as a Novel Direct-Acting Thrombolytic, Chapter 18, Pages 259~271, Section 18.3 [Non-licensed Document 12] Production of Plasma Proteins for Therapeutic Use, edited by J. Bertolini et al., Wiley, 2013 [Print ISBN: 9780470924310 | Online ISBN: 9781118356807] [Overview of the Initiative] [Means for solving the problem]

[0011] When used herein in connection with the present invention, the terms “comprise” and “having” are used to indicate the presence of the mentioned characteristics, integers, processes, or components, but not to exclude the presence or addition of one or more other characteristics, integers, processes, components, or groups thereof.

[0012] Those skilled in the art will understand that the specific embodiments disclosed herein should not be interpreted in isolation, and that this specification is intended to be interpreted in combination with the disclosed embodiments, not individually. Therefore, each embodiment can serve as a basis for modifying or limiting other embodiments disclosed herein.

[0013] Concentrations, amounts, and other numerical data may be presented or expressed herein in a range format. It should be understood that such range formats are used merely for convenience and brevity and thus should be interpreted flexibly, including not only the numerical values explicitly recited as the limits of the range but also all individual numerical values or sub-ranges subsumed within that range as if each such numerical value and sub-range were explicitly recited. By way of illustration, the numerical range "10 to 100" should be interpreted to include not only the explicitly recited values of 10 to 100 but also individual values and sub-ranges within the indicated range. Thus, this numerical range includes individual values such as 10, 11, 12, 13...97, 98, 99, 100, etc., and sub-ranges such as 10 to 40, 25 to 40, and 50 to 60. This same principle applies to ranges reciting only one numerical value such as "at least 10". Further, such interpretation shall apply regardless of the breadth of the range or feature described.

[0014] The treatment of the present invention In a first aspect, the present invention provides a method of reducing blood viscosity in a patient in need thereof, the method comprising parenteral administration of a therapeutically effective amount of fibrinogenase to the patient. One of ordinary skill in the art will understand that blood viscosity can be measured as systolic blood viscosity or diastolic blood viscosity and that any modality is applicable to the present invention. In one embodiment, the present invention provides a method of reducing diastolic blood viscosity in a patient in need thereof.

[0015] As used herein, the term "parenteral administration" refers to an administration route that results in absorption of the drug outside the gastrointestinal tract. Non-limiting examples of parenteral administration include intravenous, intramuscular, intraperitoneal, and subcutaneous. In one embodiment, fibrinogenase is administered intravenously.

[0016] In one embodiment, the patient in need of reduction of blood viscosity (e.g., diastolic blood viscosity) suffers from a wound or ulcer, which may be a chronic wound or ulcer.

[0017] As used herein, the term "ulcer" refers to a primary tissue disruption that is an internal tissue lesion within a patient; e.g., the lesion is caused by an underlying disease or other internal cause. Non-limiting examples of ulcers include: venous leg ulcers caused by cardiovascular disease or venous insufficiency, neuropathic / diabetic (foot) ulcers caused by true diabetes, pressure / decubitus ulcers caused by immobility or vascular congestion / edema in a particular area, and arterial or ischemic ulcers caused by poor perfusion (delivery of nutrient-rich blood) to the extremities.

[0018] As used herein, the term "wound" refers to a primary tissue disruption that is an external tissue lesion. Non-limiting examples of wounds include traumatic wounds caused by an accident / external force, surgically induced wounds caused by an incision, and burns caused by external heat.

[0019] Wounds and ulcers are defined as acute or chronic depending on how healing progresses. "Acute" means that the wound or ulcer progresses through the normal wound healing stages and exhibits clear signs of healing within four weeks. "Chronic" means that the wound or ulcer does not progress through the normal healing stages and shows no signs of healing within four weeks.

[0020] In a second aspect, the present invention provides a method for treating a wound or ulcer in a patient who needs it, the method comprising parenteral administration of a therapeutically effective amount of fibrinogenase to the patient.

[0021] In one embodiment, fibrinogenase is administered over a treatment period, and at one or more time points during the treatment period, the patient's plasma viscosity is reduced by at least about 1.0% compared to the patient's plasma viscosity level before treatment. For example, the patient's plasma viscosity may be reduced by at least about 1.5% compared to the patient's plasma viscosity level before treatment. In one embodiment, the patient's plasma viscosity may be reduced by at least about 2.0% compared to the patient's plasma viscosity level before treatment. In another embodiment, the patient's plasma viscosity may be reduced by at least about 2.5% compared to the patient's plasma viscosity level before treatment. In a further embodiment, the patient's plasma viscosity may be reduced by at least about 3.0% compared to the patient's plasma viscosity level before treatment. In yet another embodiment, the patient's plasma viscosity may be reduced by at least about 3.5% compared to the patient's plasma viscosity level before treatment. For example, the patient's plasma viscosity may be reduced by at least about 4.0% compared to the patient's plasma viscosity level before treatment. In one embodiment, the patient's plasma viscosity may be reduced by at least about 5.0% compared to the patient's plasma viscosity level before treatment.

[0022] In one embodiment, fibrinogenase is administered over a treatment period, and at one or more time points during the treatment period, the patient's plasma viscosity decreases by about 1.0% to about 20.0% compared to the patient's plasma viscosity level before treatment. In one embodiment, the patient's plasma viscosity may decrease by about 1.0% to about 15.0% compared to the patient's plasma viscosity level before treatment. In a further embodiment, the patient's plasma viscosity may decrease by about 1.0% to about 10.0% compared to the patient's plasma viscosity level before treatment. In yet another embodiment, the patient's plasma viscosity may decrease by about 1.0% to about 5.0% compared to the patient's plasma viscosity level before treatment. For example, the patient's plasma viscosity may decrease by about 2.5% to about 20.0% compared to the patient's plasma viscosity level before treatment. In one embodiment, the patient's plasma viscosity may decrease by about 2.5% to about 15.0% compared to the patient's plasma viscosity level before treatment. In a further embodiment, the patient's plasma viscosity may decrease by about 2.5% to about 10% compared to the patient's plasma viscosity level before treatment. In yet another embodiment, the patient's plasma viscosity may decrease by about 2.5% to about 7.5% compared to the patient's plasma viscosity level before treatment. For example, the patient's plasma viscosity may decrease by about 5.0% to about 20.0% compared to the patient's plasma viscosity level before treatment. In one embodiment, the patient's plasma viscosity may decrease by about 5.0% to about 15.0% compared to the patient's plasma viscosity level before treatment. In yet another embodiment, the patient's plasma viscosity may decrease by about 5.0% to about 10% compared to the patient's plasma viscosity level before treatment.

[0023] The main determinants of whole blood viscosity are (1) hematocrit, (2) erythrocyte deformability (i.e., the structural response of erythrocytes to applied force), and (3) plasma viscosity. This plasma viscosity is directly proportional to the concentration of certain plasma proteins, such as immunoglobulins, lipoproteins, and fibrinogen. While we do not wish to be bound by theory, we hypothesize that by administering fibrinogenase to a patient, plasma viscosity can be reduced, which may result in a corresponding reduction in whole blood viscosity. This would then improve blood circulation to the wound or ulcer, thereby increasing the rate at which the wound or ulcer heals.

[0024] As those skilled in the art will understand, there are several methods for measuring plasma viscosity. For example, plasma viscosity can be measured using a capillary viscometer, a falling body viscometer, or a rotational viscometer.

[0025] Non-limiting examples of capillary viscometers include the Ostwald U-tube viscometer and the Harkness viscometer. Non-limiting examples of falling-point viscometers include the Stoney Brook needle-drop viscometer, as well as electromagnetic viscometers, such as the VISCOlab series developed and marketed by Cambridge Viscosity. Suitable non-limiting examples of rotational viscometers include the cone-plate viscometer and the Brookfield viscometer.

[0026] Those skilled in the art will understand that the methods / instruments used to measure plasma viscosity do not define the scope of this invention. Mammalian plasma has a density very close to 1.0. Therefore, viscometers that measure either kinematic or absolute viscosity can be used to measure the reduction in plasma viscosity according to the method of this invention. Any viscosity measurement method can be applied to the measurement of plasma viscosity, provided that the same method is used to measure the viscosity levels of the patient before and after treatment.

[0027] In one particular embodiment, the absolute viscosity of a patient's plasma after fibrinogenase treatment is measured using an electromagnetic viscometer at 22°C and 1 atm. For example, the absolute viscosity of a patient's plasma after fibrinogenase treatment may be tested using a VISCOlab 4000 (Cambridge Viscosity) laboratory viscometer at 22°C and 1 atm.

[0028] In a third embodiment, the present invention relates to a method for treating a wound or ulcer in a patient requiring the treatment thereof, comprising parenteral administration of a therapeutically effective amount of fibrinogenase to the patient over a period of treatment, At one or more time points during the medication period, the patient's plasma fibrinogen level decreases by at least approximately 5% compared to the patient's fibrinogen level before treatment. Provide a method.

[0029] In one embodiment, the fibrinogen level in the patient's plasma may decrease by at least about 10% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by at least about 20% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by at least about 25% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by at least about 30% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by at least about 35% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by at least about 40% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by at least about 45% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma can be reduced by at least about 50% compared to the patient's fibrinogen level before treatment.

[0030] In one embodiment, fibrinogenase is administered over a treatment period, and at one or more time points during the treatment period, the fibrinogen level in the patient's plasma is reduced by about 5% to about 70% compared to the patient's pre-treatment fibrinogen level. In one embodiment, the fibrinogen level in the patient's plasma may be reduced by about 15% to about 70% compared to the patient's pre-treatment fibrinogen level. In one embodiment, the fibrinogen level in the patient's plasma may be reduced by about 25% to about 70% compared to the patient's pre-treatment fibrinogen level. In one embodiment, the fibrinogen level in the patient's plasma may be reduced by about 35% to about 70% compared to the patient's pre-treatment fibrinogen level. In one embodiment, the fibrinogen level in the patient's plasma may be reduced by about 45% to about 70% compared to the patient's pre-treatment fibrinogen level.

[0031] In one embodiment, the fibrinogen level in the patient's plasma may decrease by about 10% to about 65% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by about 10% to about 60% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by about 10% to about 55% compared to the patient's fibrinogen level before treatment. In one embodiment, the fibrinogen level in the patient's plasma may decrease by about 10% to about 50% compared to the patient's fibrinogen level before treatment.

[0032] As those skilled in the art will understand, there are several methods used to clinically measure fibrinogen levels in plasma. Non-exclusive examples include: • Total coagulating fibrinogen (Blomback and Blomback method) • Coagulation time assay / Clauss assay, • Radioimmunodiffusion method by Mancini et al. • Total amount of coagulating fibrinogen using the turbidimetric assay by Ellis and Stransky • Immunological assays, ·ChromotimeSystem, and • Prothrombin time (PT)-derived fibrinogen assay in ACL coagulation analyzer.

[0033] All of these assays are common knowledge and familiar to those skilled in the art, and numerous discussions exist in the literature on various techniques. Two such discussions are Palareti G et al., *Fibrinogen assays: a collaborative study of six different methods*, CISMEL Clin Chem. May 1991; 37(5): pp. 714-719, and Mackie et al., *Guidelines on fibrinogen assays*, British Journal of Haematology, 2003, 121, pp. 396-404, the contents of which are incorporated herein by reference.

[0034] Those skilled in the art will understand that the assays used to measure plasma fibrinogen levels do not define the scope of this invention. This invention relates to the relative decrease in plasma fibrinogen levels before and after treatment. Any fibrinogen assay method can be applied to the measurement of plasma fibrinogen levels, provided that the same method is used to measure the patient's fibrinogen levels before and after treatment.

[0035] In one embodiment, plasma fibrinogen levels are determined by the coagulation time / Clauss method, see Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrunogens. Acta Haematol 1957;17;237-246, the contents of which are incorporated herein by reference.

[0036] Simply put, the Clauss assay is a fibrinogen activity test. A test plasma sample is diluted with a high concentration of thrombin (ranging from 35 to 200 U / ml, but typically around 100 U / ml), and the coagulation time is measured. The test results are compared to a calibration curve prepared by coagulating serial dilutions of a reference plasma sample with a known fibrinogen concentration, and the results are obtained in g / l units. The time it takes for a thrombus to form is positively correlated with the amount of active fibrinogen present.

[0037] In one embodiment, the treatment method of the present invention aims to improve the healing of venous lower leg ulcers. In one embodiment, the treatment method of the present invention aims to improve the healing of neuropathic or diabetic ulcers. In one embodiment, the treatment method of the present invention aims to improve the healing of pressure ulcers or compression ulcers. In one embodiment, the treatment method of the present invention aims to improve the healing of arterial or ischemic ulcers.

[0038] In some embodiments, the treatment methods of the present invention aim to improve the healing of chronic wounds and ulcers. For example, chronic venous leg ulcers, chronic diabetic ulcers, chronic compression ulcers, chronic ischemic ulcers, and combinations thereof.

[0039] fibrinogenase Unexpectedly, the inventors discovered that systemic administration of fibrinogenase successfully improved the treatment of wounds and / or ulcers in patients. While not wishing to be constrained by theory, the inventors hypothesize that administering fibrinogenase to patients with (chronic) wounds or ulcers will cause the protease to break down fibrinogen in the patient's plasma and reduce its concentration. This would then reduce the patient's blood viscosity, improve microcirculation to the wound or ulcer, and thereby increase the rate at which the wound or ulcer heals.

[0040] In this specification, "protease" means a molecule that breaks down large proteins into smaller proteins and / or peptides.

[0041] "Fibrinogenase" refers to a protease capable of breaking down the protein fibrinogen. Fibrinogenases can be classified into α, β, and γ-fibrinogenases based on their specificity in cleaving fibrinogen polypeptide chains. The fibrinogenase used in the method of the present invention may be selected from the group consisting of α-fibrinogenase, β-fibrinogenase, γ-fibrinogenase, and combinations thereof. The fibrinogenase found useful in the present invention may be produced by recombinant organism or isolated from natural sources.

[0042] In one embodiment, the fibrinogenase is selected from the group consisting of metallo-α-fibrinogenase, allium-α-fibrinogenase, and combinations thereof.

[0043] In certain embodiments, the fibrinogenase used in the method of the present invention is plasmin. The plasmin found useful in the present invention may be produced by recombinant production or may be derived from plasminogen isolated from a natural source, for example, from human plasma.

[0044] Those skilled in the art will understand that the specific embodiments disclosed in the preceding paragraphs should not be interpreted in isolation, and that this specification is intended to be disclosed in combination with other embodiments, as opposed to these embodiments being disclosed individually.

[0045] Plasmin The naturally occurring circulating human plasminogen described in Sequence ID No. 1 is a single-chain protein containing 791 amino acid residues, 24 intrachain disulfide crosslinks, 5 kringle domains, 1 serine protease domain, and 1 pre-activated peptide (PAP). The locations of these domains in Sequence ID No. 1 are outlined in Table 1 below.

[0046] [Table 1]

[0047] Plasminogen is produced as Glu-plasminogen and Lys-plasminogen, depending on whether the N-terminal amino acid is glutamic acid or lysine. Glu-plasminogen consists of the full-length amino acid sequence specified by the gene sequence (excluding the precursor peptide). Lys-plasminogen is the result of cleavage between Lys-77 and Lys-78 of Glu-plasminogen. Glu-plasminogen is the dominant form of plasminogen present in human plasma.

[0048] Upon secretion into plasma, plasminogen can be converted to plasmin by the action of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). t-Pa / u-PA cleave the Arg561-Val562 peptide bond in the plasminogen enzyme precursor. The resulting plasmin molecule is a double-stranded disulfide-linked serine protease with trypsin-like specificity (cleavage after Lys and Arg).

[0049] The amino-terminal heavy chain of plasmin consists of five kringle domains, each containing approximately 80 amino acid residues. These kringle domains are responsible for plasmin's interactions with other proteins, such as polymer fibrin and the plasmin inhibitor α2-antiplasmin.

[0050] The C-terminal light chain of plasmin is homologous to that of trypsin and is a typical serine protease containing the classic serine protease catalytic triad: His603, Asp646, and Ser741.

[0051] As used herein, the term "plasmin" shall be construed to mean the following in a therapeutically effective amount: Wild-type (human) plasmin protein, That functional mutant, The functional fragment, or A combination of those.

[0052] Figure 1 discloses schematic diagrams of several plasmin variants and mutants within the scope of the present invention. Mutants having kringle domains 1-5 in various permutations linked to the serine protease component are within the scope of the present invention. Minor variations in the amino acid sequence are irrelevant, provided that the motif outlined in Figure 1 is maintained. The information outlined in Sequence ID No. 1, Table 1, and Figure 1 will provide sufficient indication and clarity to those skilled in the art that plasmin mutants fall within the scope of the present invention.

[0053] For example, "plasmin" is (Human) Glu-plasmin, (Human) Lys-plasmin, Midi-plasmin, Mini-plasmin, Microplasmin (for example, disclosed in U.S. Patent No. 4,774,087, which is incorporated in whole by reference herein, or in the commercially available plasmin mutant ocriplasmin), Deltaplasmin (for example, disclosed in whole in U.S. Patent No. 8,420,079, which is incorporated herein by reference), and These combinations This includes, but is not limited to, the following:

[0054] In one embodiment, plasmin is (human)glu-plasmin. In some embodiments, plasmin is (human)lys-plasmin. In other embodiments, plasmin is a mixture of glu- and lys-plasmin.

[0055] The unexpected effectiveness of plasmin in the treatment of wounds and ulcers using plasmin viscosity reduction is particularly surprising given that systemic / intravenous thrombolytic therapy with plasmin had largely been considered ineffective; see Marder VJ. Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin. J Thromb Haemost. 2011;9 Suppl 1:364-373. Free plasmin (not bound to fibrin) released into the plasma is immediately neutralized and inactivated by circulating protease inhibitors, such as α2-antiplasmin.

[0056] Furthermore, the ability of plasmin to induce non-localized effects on wound / ulcer healing is entirely unexpected. The prevailing scientific view is that plasmin's role in wound healing is less significant than that of plasminogen, as its action is strictly localized to the breakdown of fibrin during the remodeling phase of the wound healing process. Plasminogen is a preferred candidate for pharmacological intervention due to its ability to activate intracellular signaling events, generate an improved inflammatory response, and its long plasma half-life.

[0057] Those skilled in the art will understand that the specific embodiments disclosed in the preceding paragraphs should not be read in isolation, and that this specification is intended to disclose these embodiments in combination with other embodiments, rather than individually. For example, each of the embodiments disclosed in the preceding paragraphs should be read in express combination with each of the embodiments disclosed from the section on the treatment of the present invention to the section immediately preceding the current paragraph, or with any permutation of two or more embodiments disclosed herein.

[0058] dosage In one embodiment of the method of the present invention, fibrinogenase may be administered to a patient in at least one dose at a concentration of about 1 mg / kg to about 100 mg / kg. For example, about 1 mg / kg to about 50 mg / kg, for example, about 1 mg / kg to about 30 mg / kg, for example, about 1 mg / kg to about 10 mg / kg.

[0059] In some embodiments of the method of the present invention, fibrinogenase may be administered to a patient in at least one dose at a concentration of about 5 mg / kg to about 30 mg / kg, for example, about 5 mg / kg to about 20 mg / kg, for example, about 5 mg / kg to about 10 mg / kg.

[0060] In some embodiments of the method of the present invention, fibrinogenase may be administered to a patient in at least one dose at a concentration of about 2 mg / kg to about 20 mg / kg, for example, about 4 mg / kg to about 16 mg / kg, for example, about 6 mg / kg to about 12 mg / kg.

[0061] In further embodiments of the method of the present invention, fibrinogenase may be administered to a patient in at least one dose at a concentration of about 2 mg / kg to about 10 mg / kg, for example, about 4 mg / kg to about 10 mg / kg, for example, about 6 mg / kg to about 10 mg / kg.

[0062] The present invention also provides the administration of fibrinogenase to patients who require it, as part of a multi-dose regimen.

[0063] For example, fibrinogenase may be administered as an initial dose of approximately 5 mg / kg to 30 mg / kg on day 1 of the treatment period, followed by doses of approximately 5 mg / kg to 30 mg / kg per dose during the subsequent treatment period. For example, an initial dose of approximately 5 mg / kg to 20 mg / kg on day 1 of the treatment period, followed by doses of approximately 5 mg / kg to 20 mg / kg per dose during the subsequent treatment period. For example, an initial dose of approximately 5 mg / kg to 15 mg / kg on day 1 of the treatment period, followed by doses of approximately 5 mg / kg to 15 mg / kg per dose during the subsequent treatment period. For example, an initial dose of approximately 6 mg / kg to 12 mg / kg on day 1 of the treatment period, followed by doses of approximately 6 mg / kg to 12 mg / kg per dose during the subsequent treatment period.

[0064] A multi-dose period may include approximately 3 to 30 doses up to the total cumulative dose. A multi-dose period may last approximately 1 to 10 weeks. Multiple partial doses may be administered at intervals of approximately 1 to 30 days.

[0065] A multi-dose period may include approximately 3 to 15 doses up to the total cumulative dose. A multi-dose period may last approximately 1 to 5 weeks. Multiple partial doses may be administered at intervals of approximately 1 to 10 days.

[0066] Those skilled in the art will understand that the specific embodiments disclosed in the preceding paragraphs should not be read in isolation, and that this specification is intended to disclose these embodiments in combination with other embodiments, rather than individually. For example, each of the embodiments disclosed in the preceding paragraphs should be read in express combination with each of the embodiments disclosed from the section on the treatment of the present invention to the section immediately preceding the current paragraph, or with any permutation of two or more embodiments disclosed herein.

[0067] For example, all embodiments of drug delivery disclosed in the paragraphs belonging to this section are applicable, with necessary modifications, when the fibrinogenase is plasmin. Similarly, all embodiments of drug delivery disclosed in the paragraphs shall be interpreted as directly applicable to plasmins selected from the group consisting of Glu-plasmin, Lys-plasmin, Midi-plasmin, Mini-plasmin, Micro-plasmin, Delta-plasmin, and combinations thereof.

[0068] Pharmaceutical composition of the present invention The present invention provides a treatment method in which fibrinogenase is administered to a patient as a component of a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier. The at least one pharmaceutically acceptable carrier may be selected from adjuvants and vehicles. The at least one pharmaceutically acceptable carrier may include any solvent, diluent, other liquid vehicle, dispersant, suspension aid, surfactant, isotonic agent, thickener, emulsifier, or preservative suitable for the desired specific dosage form.

[0069] Suitable carriers are described in Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. DB Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and JC Boylan, 1988–1999, Marcel Dekker, New York, the contents of which are incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, physiological saline, Ringer's solution, glycol, dextrose solution, buffered solutions (e.g., phosphoric acid, glycine, sorbic acid, and potassium sorbate), and 5% human serum albumin. Liposomes and non-aqueous vehicles, such as glyceride mixtures of saturated vegetable fatty acids, and fixed oils (e.g., peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil) may also be used depending on the route of administration.

[0070] The pharmaceutical composition used in the method of the present invention may be formulated for parenteral administration. The pharmaceutical composition may be enclosed in glass or plastic ampoules, disposable syringes, sealed bags, or multi-dose vials.

[0071] In one embodiment, the pharmaceutical composition of the present invention is formulated for administration by intravenous injection. The formulation can be administered continuously by infusion or bolus injection.

[0072] The pharmaceutical compositions of the present invention may be presented in unit dosing unit form, that is, as physically distinct units intended as unit dosing to the target to be treated.

[0073] A sterile injection solution of the pharmaceutical composition of the present invention can be prepared by incorporating the active molecule, along with one or a combination of components, in the required amount with a suitable solvent, and then sterilizing by filtration.

[0074] In one embodiment, fibrinogenase (e.g., plasmin) may be formulated as a lyophilized powder for reconstitution. In the case of a sterile powder for reconstitution as a sterile injection solution, the preparation method involves obtaining a powder from a pre-sterilized filtered solution to which the active ingredient has been added any additional desired components by vacuum drying and lyophilization.

[0075] Unless any conventional culture medium or drug is incompatible with the active molecule and / or the administration route of the present invention, its use in the composition is intended to be within the scope of the present invention.

[0076] When the fibrinogenase used in the method of the present invention is plasmin, the pharmaceutical composition used in the method of the present invention may have an acidic pH. For example, the pharmaceutical composition may have a pH of about 2.5 to about 4. In the context of this specification, pH measurement is assumed to be performed in water at 25°C.

[0077] In one embodiment, the pharmaceutical composition containing plasmin may further contain a buffering agent to maintain an acidic pH. In one embodiment, the buffering agent may be selected from the group consisting of carboxylic acids, at least one amino acid, derivatives of at least one amino acid, dipeptides, oligopeptides containing at least one amino acid, and combinations thereof. For example, the buffering agent may be selected from formic acid, acetic acid, citric acid, hydrochloric acid, lactic acid, malic acid, tartaric acid, benzoic acid, serine, threonine, methionine, glutamine, alanine, glycine, isoleucine, valine, alanine, aspartic acid, derivatives thereof, and combinations thereof.

[0078] The pharmaceutical compositions of the present invention, comprising plasmin, may further comprise at least one stabilizer. The stabilizer may be pharmaceutically acceptable amino acids, or carbohydrates including but not limited to monosaccharides, disaccharides, polysaccharides, and polyhydric alcohols. For example, pharmaceutically acceptable carbohydrate stabilizers intended to be within the scope of the present invention include, but not limited to, sugars such as sucrose, glucose, fructose, lactose, trehalose, maltose, and mannose, and sugar alcohols including but not limited to sorbitol and mannitol. Polysaccharides including but not limited to dextrin, dextran, glycogen, starch, and cellulose, or any combination thereof pharmaceutically acceptable to human or animal patients, are intended to be within the scope of the present invention.

[0079] In one embodiment, the stabilizer may be selected from the group consisting of glycerol, niacinamide, glucosamine, thiamine, citrulline, and inorganic salts such as sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or any combination thereof, but not limited to these.

[0080] In one embodiment, fibrinogenase (e.g., plasmin) may constitute at least 20% by mass of the total protein content of the pharmaceutical composition of the present invention. For example, plasma protein proteases may constitute about 30% or more by mass, 40% or more by mass, 50% or more by mass, 60% or more by mass, 70% or more by mass, 75% or more by mass, 80% or more by mass, 85% or more by mass, 90% or more by mass, 93% or more by mass, 95% or more by mass, 96% or more by mass, 97% or more by mass, 98% or more by mass, or 99% or more by mass of the total protein content of the pharmaceutical composition of the present invention.

[0081] Those skilled in the art will understand that the specific embodiments disclosed in the preceding paragraphs should not be read in isolation, and that this specification is intended to disclose these embodiments in combination with other embodiments, rather than individually. For example, each of the embodiments disclosed in the preceding paragraphs should be read in express combination with each of the embodiments disclosed from the section on the treatment of the present invention to the section immediately preceding the current paragraph, or with any permutation of two or more embodiments disclosed herein.

[0082] For example, each of the embodiments disclosed in the preceding paragraph is applicable when the fibrinogenase is a plasmin, with necessary modifications. Similarly, all embodiments disclosed in the preceding paragraph are to be interpreted as directly applicable to plasmins selected from the group consisting of Glu-plasmin, Lys-plasmin, Midi-plasmin, Mini-plasmin, Micro-plasmin, Delta-plasmin, and combinations thereof.

[0083] Additional features and advantages of the present invention will become clearer in the accompanying drawings. [Brief explanation of the drawing]

[0084] [Figure 1] This is a schematic diagram of several plasmin variants and mutants within the scope of the present invention. [Figure 2] This figure plots the effects of plasmin and its variants on fibrinogen concentration in vitro. [Figure 3] This graph plots the effect of full-length plasmin on plasma viscosity at various concentrations in pooled human plasma samples. [Figure 4] This figure shows the wound healing research protocol according to the present invention. [Figure 5] This figure plots the effects of plasmin and a control molecule on fibrinogen concentration in rats over the study period. [Figure 6] This figure plots the effects of plasmin and a control molecule on wound size reduction in rats over the study period. [Figure 7] This figure shows the effects of plasmin and a control on wound histology in rats. [Figure 8] This figure shows the effects of plasmin and a control molecule on wound histology in rats. [Modes for carrying out the invention]

[0085] Those skilled in the art will readily understand that the examples disclosed herein are merely generalized examples, and that other configurations and methods are possible and encompassed by the present invention that can reproduce the present invention. [Examples]

[0086] Effects of plasmin and its variants on fibrinogen concentration in vitro In vitro studies were performed to determine the effects of different plasmin species on fibrinogen cleavage at different concentrations. The various plasmin species tested are labeled next to their corresponding plots in Figure 2. The plasmin species were titrated into human plasma at the indicated concentrations, and the residual fibrinogen content was assayed using the thrombin-coagulating fibrinogen assay reported by Blomback (Blomback B., Blomback M. Purification of human and bovine fibrinogen. Arkh. Kem.10, 415, 1956). Briefly, the principle of this method is to isolate thrombin-coagulating material from citrated plasma. Once a thrombus is formed by the reaction of thrombin and fibrinogen, it is thoroughly washed and dissolved in alkaline urea for spectrophotometric measurement of fibrin concentration.

[0087] Experimental Details: 20 μl of TBS was added to 230 μl of citrated plasma, and 10 μl of 0.239 mg / ml thrombin was immediately added to the thrombotic plasma (10-fold diluted thrombin, 2.39 mg / ml, 1000 units, obtained from Enzyme Research). The tubes were incubated at 37°C for 3 minutes, then vortexed, and centrifuged at 14,000 rpm for 3 minutes at room temperature in a benchtop Eppendorf centrifuge. The supernatant (serum) was removed, and 1 ml of TBS was added to each tube. After intensive vortexing, the tubes were centrifuged again at 14,000 rpm. The supernatant was removed, and 1 ml of 1 M NaOH was added to each tube to dissolve the thrombus. The tubes were incubated at 70-80°C for 2-4 minutes, cooled, and the absorbance at 280 nm was measured using a spectrophotometer.

[0088] Incubation with plasmin: (Various amounts of plasmin according to Figure 2, 5 minutes at 37°C) Place the tubes containing plasma in a water bath at 37°C. Add various amounts of plasmin (0-20 μl of 5 mg / ml solution) to each tube with a 30-second delay. Stop the 5-minute incubation by adding 10 μl of thrombin. Proceed with the remainder of the assay as described above. Perform three consecutive concentration points.

[0089] Full-length plasmin was prepared according to the procedures / methods detailed in Novokhatny, V. et al., Acid Stabilised Plasmin as a Novel Direct-Acting Thrombolytic, Chapter 18, pp. 259-271, Section 18.3, and Production of Plasma Proteins for Therapeutic Use, J. Bertolini et al., Wiley, 2013 [Print ISBN: 9780470924310 | Online ISBN: 9781118356807], which are known to those skilled in the art and whose contents are incorporated herein by reference. Shortened plasmin mutants were prepared recombinantly using manufacturing processes within the general knowledge common to those skilled in the art.

[0090] The full-length plasmin used in all experiments outlined herein was primarily a mixture of lys-plasmin and trace amounts of glue-plasmin. Over time, lys-plasmin would convert any glue-plasmin in the mixture into lys-plasmin. "Full-length plasmin" herein refers to this mixture in unspecified proportions, but with a significant excess of lys-plasmin.

[0091] Figure 2 clearly shows that the addition of plasmin and its variants at progressively increasing concentrations leads to a decrease in the concentration of coagulating fibrinogen in human plasma. Full-length / unshortened plasmin at concentrations above 2.4 μM (dose equivalent of 8 mg / kg) completely depleted all coagulating fibrinogen in human plasma samples.

[0092] The effect of plasmin on fibrinogen was most pronounced with full-length plasmin. Shortened species of plasmin, such as mini- or micro-plasmin, exhibited a lower effect on coagulating fibrinogen levels in human plasma. The addition of ε-aminocaproic acid, a known inhibitor of kringle-mediated interactions in plasmin, resulted in a significant reduction in plasmin's protease activity against fibrinogen (thin black line).

[0093] These in vitro experiments using human plasma suggest that full-length plasmin can be used as a tool to control circulating fibrinogen levels in human patients in a controllable manner. [Examples]

[0094] Exovivoviscosity research To test the effect of full-length plasmin on plasma viscosity, a series of experiments were conducted in which pooled human plasma was incubated with gradually increasing concentrations of plasmin for 5 minutes. 360 μl of 2.78 mg / ml plasmin was added to 10 ml of plasma, and after 5 minutes of incubation, a 1.5 ml aliquot was placed in a Viscolab 4000 (Cambridge Viscosity) laboratory viscometer. The data, expressed in centipoise units, were plotted against plasmin concentration, as shown in Figure 3. As can be seen in Figure 3, a significant decrease in viscosity from 1.725 ± 0.015 to 1.63 ± 0.0035 cP was observed.

[0095] The scale inserted in the upper half of the graph provides an illustrative reference for equivalent amounts compared to drug administration to animals. For example, the 8 mg / kg dose used in a rat wound healing study would correspond to a plasma concentration of approximately 0.2 mg / ml of plasmin, assuming that the blood volume of a 500g rat is approximately 35-40 ml, of which plasma is approximately 20 ml. [Examples]

[0096] Evaluation of the effects of systemic administration of plasmin in a wound healing model of type 2 diabetes. Male Zucker diabetic adipose rats (ZDF-Leprfa / Crl, obese) with JVC catheters were obtained from Charles River. The rats were 16 weeks old and weighed 400–450 g. The rats had blood glucose levels above 14 mmol / L or 252 mg / dl. The study was blinded regarding treatment during the survival period.

[0097] Rats were divided into three groups: Group 1 - normal physiological saline, Group 2 - recombinant albumin at 2.8 mg / ml and 8 mg / kg, and Group 3 - full-length plasmin at 2.78 mg / ml and 8 mg / kg.

[0098] Each group consisted of 10 rats. A dosage of 3 mL / kg was used, administered at a frequency of 10 days. The entire study period was 15 days.

[0099] Animals were anesthetized using an isoflurane / oxygen gas chamber. A metal rod (25 g, 1 cm in diameter) was heated to 95–100°C by immersion in boiling water. The rod was immediately positioned vertically for 6 seconds on the skin of the back of a depilated rat three days prior to wound formation, without applying further pressure. After wound formation, the rats were placed in individual cages, and the wounds were left untreated. Approximately 24 hours after burn induction, 0.1 mL of the test and reference materials were administered intravenously once daily for the duration of the treatment. During the study, evaluations included checking mortality, clinical observation, and weight assessment.

[0100] Daily direct visual observation of the burn wound was performed from immediately after burn induction until the day of autopsy, and daily digital images of the burn wound, along with the surrounding skin wound area, were obtained. The outline of the wound margin and the area covered by scab / crust were drawn on a sterile transparent sheet every two days (days 1, 3, 5, 7, 9, 11, 13, and 15), and the area contained within the outline was measured planarly by computer analysis. Blood samples were collected from all animals at the time of scheduled autopsy for clinicopathological examination (hematology and coagulation).

[0101] At each autopsy, all pre-terminal and surviving animals were visually observed, and representative wounded / burned skin and / or unwounded skin samples were collected. Histopathological evaluation was performed on wounded / burned skin samples obtained from five animals per group. In addition, wounded / burned skin and unwounded abdominal skin samples were collected from five animals per group and frozen in liquid nitrogen.

[0102] An overview of the entire test protocol is shown in Figure 4, and the analysis performed is outlined below.

[0103] 1. First, the total blood count (CBC) was evaluated along with the fractions. Several parameters were studied: red blood cell count (RBC), red blood cell distribution width (RDW), mean corpuscular volume (MCV), hematocrit, hemoglobin (Hgb, Hb), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell count (WBC), percentage and absolute values ​​of fractions / white blood cell fractions, and platelet count.

[0104] 2. The following clinical chemistry parameters were studied: alanine aminotransferase (u / l), aspartate aminotransferase (u / l), alkaline phosphatase (u / l), blood urea nitrogen (mg / dl), total bilirubin (mg / dl), direct bilirubin (mg / dl), total protein (g / dl), albumin (g / dl), creatine (mg / dl), creatine kinase (u / l), cholesterol (mg / dl), triglycerides (mg / dl), glucose (mg / dl), etc.

[0105] 3. Finally, the parameters of the coagulation panel were evaluated: prothrombin time (PT) (seconds), activated partial thromboplastin time (APTT) (seconds), and fibrinogen (FIB) (mg / dl). [Examples]

[0106] Results from the rat wound model in Example 3 Groups 1-3 showed little difference among the parameters outlined in paragraphs 1 and 2 above. Results are not shown. However, with respect to blood fibrinogen levels, group 3 (plasmin) showed a significant decrease compared to the control groups (groups 1 and 2).

[0107] Figure 5 plots the fibrinogen levels (mg / dl) recorded in the three groups over the study period (n=5 rats). Rats treated with full-length plasmin showed a reduction in fibrinogen concentration throughout the study period.

[0108] Table 2 shows the mean wound size (n=5 rats) at the end of the study for rats treated with plasmin versus those treated with saline. Furthermore, the results are plotted in Figure 6.

[0109] [Table 2] [Examples]

[0110] Sample Pathology Two sections of the wound, obtained from both sides of the wound site, were evaluated by a pathologist in a blinded manner. The histological scoring criteria used are outlined below, and the results are illustrated in Figure 7.

[0111] Score the inflammation across the wound site on the following scale from 0 to 5: 0. None, 1. Minimal - Aggregates of inflammatory cells, such as neutrophils, macrophages, and lymphocytes, are almost undetectable throughout the wound bed. 2. Mild - Significantly above detectable levels, with several clusters of inflammatory cells throughout the wound bed. 3. Moderate to obvious inflammatory cells are scattered or aggregated throughout the wound bed. 4. Marked - Diffuse-like infiltration of inflammatory cells covering 50-75% of the wound bed. 5. Severe - Diffuse infiltration of inflammatory cells covering more than 75% of the wound bed.

[0112] Granulation tissue is scored on the following scale from 0 to 3: 0. Granulation tissue is not present in the wound bed. 1. A minimal amount of granulation tissue is present in the wound bed. 2. A moderate amount of granulation tissue is present in the wound bed. 3. Robust granulation tissue is present in the wound bed.

[0113] The percentage of re-epithelialization is approximately 5% of the defect covered by the epithelial surface.

[0114] The results are plotted in Figures 7A to 7C, and representative slides of the wound sites are provided in Figure 8. The results show that inflammation was significantly reduced in the groups treated with full-length plasmin compared to control groups 1 and 2. Inflammation consisted mainly of macrophages, lymphocytes, and plasma cells, but neutrophils were present in areas of more severe inflammation in some animals that had not yet undergone complete re-epithelialization.

[0115] While there were no significant differences between groups in granulation tissue and re-epithelialization percentage, the plasmin-treated group clearly showed a trend toward increased re-epithelialization compared to the control group. This improvement was observed on both the left and right sides, and wound bed coverage was enhanced by the transition of new epithelial tissue into mature granulation tissue. Granulation tissue was prominent in the wound bed in all groups.

[0116] The aforementioned study demonstrates that the full-length plasmin treatment group exhibits improved wound healing accompanied by approximately a 25% reduction in circulating plasma fibrinogen levels.

[0117] Sequence List The sequences mentioned in the preceding text are outlined below in fasta format. In the event of any discrepancy between the sequences listed in this document and the corresponding sequences in the attached sequence listing, the sequence listed in this document shall take precedence for the purpose of correcting the error.

[0118] Sequence ID 1: Human Plasminogen Protein Sequence

[0119] [ka]

Claims

1. A pharmaceutical composition comprising a therapeutically effective amount of fibrinogenase for the treatment of wounds or ulcers in a patient in need thereof, the pharmaceutical composition being formulated for parenteral administration.

2. 2. The pharmaceutical composition of claim 1, wherein the parenteral administration is an administration route selected from the group consisting of intravenous, intramuscular, intraperitoneal, and subcutaneous.

3. The pharmaceutical composition of claim 1 , wherein the fibrinogenase is administered intravenously.

4. 4. The pharmaceutical composition of claim 1, wherein the fibrinogenase is selected from the group consisting of α-fibrinogenase, β-fibrinogenase, γ-fibrinogenase, metallo-α-fibrinogenase, allium-α-fibrinogenase, plasmin, and combinations thereof.

5. 5. The pharmaceutical composition of claim 1, wherein the fibrinogenase is plasmin.

6. 6. The pharmaceutical composition of claim 5, wherein the plasmin is selected from the group consisting of Glu-plasmin, Lys-plasmin, midi-plasmin, mini-plasmin, micro-plasmin, delta-plasmin, and combinations thereof.

7. 7. The pharmaceutical composition of claim 6, wherein the plasmin is selected from the group consisting of Glu-plasmin, Lys-plasmin, and combinations thereof.

8. The fibrinogenase is administered over a dosing period; At one or more time points during the dosing period, the patient's plasma viscosity is reduced by at least about 1.0%, as compared to the patient's pre-treatment plasma viscosity level.

8. A pharmaceutical composition according to any one of claims 1 to 7.

9. The fibrinogenase is administered over a dosing period; at one or more time points during the dosing period, the patient's plasma viscosity is reduced in the range of about 1.0% to about 20.0%, as compared to the patient's pre-treatment plasma viscosity level.

9. A pharmaceutical composition according to any one of claims 1 to 8.

10. 10. The pharmaceutical composition of any one of claims 1 to 9, wherein the patient is suffering from an ulcer, and the ulcer is selected from the group consisting of venous leg ulcers, diabetic ulcers, pressure ulcers, ischemic ulcers, and combinations thereof.

11. 11. The pharmaceutical composition of any one of claims 1 to 10, wherein the fibrinogenase is administered to the patient in at least one dose at a concentration of about 1 mg / kg to about 100 mg / kg.

12. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein the fibrinogenase is administered at an initial dose of about 3 mg / kg to about 30 mg / kg on day 1 of an administration period, followed by about 3 mg / kg to about 30 mg / kg per dose during multiple dosing periods.

13. 13. The pharmaceutical composition of claim 12, wherein the multiple dosing period can include from about 3 to about 30 administrations, up to a total cumulative dose.

14. 14. The pharmaceutical composition of claim 12 or 13, wherein the multiple dosing period can be for a period of about 1 to about 10 weeks.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the pharmaceutical composition has an acidic pH.

16. A pharmaceutical composition described in any one of claims 1 to 15, wherein the fibrinogenase is administered to the patient over a dosing period and at one or more time points during the dosing period, the fibrinogen level in the patient's plasma is reduced by at least about 5% compared to the patient's pre-treatment fibrinogen level.

17. 17. The pharmaceutical composition of claim 16, wherein at one or more time points during the dosing period, the fibrinogen level in the patient's plasma is reduced by between about 5% and about 70%, compared to the patient's pre-treatment fibrinogen level.

18. A pharmaceutical composition comprising a therapeutically effective amount of fibrinogenase for reducing blood viscosity in a patient in need thereof, the pharmaceutical composition being formulated for parenteral administration.

19. 20. The pharmaceutical composition of claim 18, wherein the parenteral administration is a route of administration selected from the group consisting of intravenous, intramuscular, intraperitoneal, and subcutaneous.

20. 20. The pharmaceutical composition of claim 18, wherein the fibrinogenase is administered intravenously.

21. 21. The pharmaceutical composition of any one of claims 18 to 20, wherein the fibrinogenase is selected from the group consisting of α-fibrinogenase, β-fibrinogenase, γ-fibrinogenase, metallo-α-fibrinogenase, allium-α-fibrinogenase, plasmin, and combinations thereof.

22. 22. The pharmaceutical composition of any one of claims 18 to 21, wherein the fibrinogenase is plasmin.

23. 23. The pharmaceutical composition of claim 22, wherein the plasmin is selected from the group consisting of Glu-plasmin, Lys-plasmin, midi-plasmin, mini-plasmin, micro-plasmin, delta-plasmin, and combinations thereof.

24. 24. The pharmaceutical composition of claim 23, wherein the plasmin is selected from the group consisting of Glu-plasmin, Lys-plasmin, and combinations thereof.

25. 25. The pharmaceutical composition of any one of claims 18 to 24, wherein the fibrinogenase is administered to the patient in at least one dose at a concentration of about 1 mg / kg to about 100 mg / kg.

26. 26. The pharmaceutical composition of any one of claims 18 to 25, wherein the fibrinogenase is administered at an initial dose of about 3 mg / kg to about 30 mg / kg on day 1 of a dosing period, followed by about 3 mg / kg to about 30 mg / kg per dose during a multiple dosing period.

27. 27. The pharmaceutical composition of claim 26, wherein the multiple dosing period can include from about 3 to about 30 administrations, up to a total cumulative dose.

28. 28. The pharmaceutical composition of claim 26 or 27, wherein the multiple dosing period can be for a period of about 1 to about 10 weeks.

29. The pharmaceutical composition of any one of claims 18 to 28, wherein the pharmaceutical composition has an acidic pH.

30. 30. The pharmaceutical composition of any one of claims 18 to 29, wherein the patient in need thereof is a patient suffering from a wound or ulcer.

31. 31. The pharmaceutical composition of any one of claims 18 to 30, wherein the patient is suffering from an ulcer, the ulcer being selected from the group consisting of venous leg ulcers, diabetic ulcers, pressure ulcers, ischemic ulcers, and combinations thereof.

32. 32. The pharmaceutical composition of any one of claims 18 to 31, wherein the blood viscosity is diastolic blood viscosity.